State Medicaid and GLP-1s: the same federal permission, forty-two different answers
One sentence of federal law sits underneath all of this: agents used for anorexia, weight loss or weight gain are on the list of drug classes a program may exclude. It is permission, not a rule, and what each state did with that permission is the only thing that decides whether a prescription is paid for. We read the published coverage documents behind 51 state programs, and they are not variations on a theme. They are 51 separate decisions.
What this comes down to
- The federal statute lists agents when used for anorexia, weight loss, or weight gain first among the drug classes a program may exclude or restrict. Everything below that is a state choice.
- Across the 51 state programs we have documented, 24 carry a captured quote that says a GLP-1 is excluded, not covered, discontinued or will deny for weight loss.
- The mechanism differs even where the answer is the same. One state implements it as a claim edit on the drug code; another as a footnote under a formulary table; another as a line item in an enacted budget.
- Coverage moves in both directions. One program we documented ended obesity coverage in October 2025 and reinstated it that December by the governor's directive.
- Programs documented51
- Quoting an exclusion or non-coverage phrase24
The federal sentence everything else hangs off
The Medicaid statute sets out the drugs or classes of drugs whose medical uses may be excluded from coverage or otherwise restricted, and the first item on that list is agents when used for anorexia, weight loss, or weight gain[1]. Read it carefully and it does two things at once: it makes a weight-loss exclusion lawful anywhere, and it makes coverage lawful anywhere too. Neither answer is federally required, which is why a drug that is free in one state is a cash purchase across the line. Medicare Part D then adopts that same list by reference, as it stood on December 8, 2003[2]. The Medicare side of the same arithmetic, and why the appeals process cannot reach it, is the prior-authorization article.
What the state records hold. A State coverage records search finds 24 results; the same search for state records that name a GLP-1 at all finds 46.
Four shapes the same decision takes
The most useful thing about reading these documents side by side is that the mechanism tells you what kind of appeal, if any, exists. New York implements its exclusion as a claim edit on the drug code, printed in a numbered monthly update with the statutory basis in the same row as the denial code — there is nothing to argue about at the counter, because no human is reading anything. California removed three drugs from its contract list as a line item under pharmacy savings in an enacted budget, and approvals already granted expired the day before the change.
Florida never excluded anything; it built a criteria wall instead, and the criteria are diabetes criteria — a type 2 diagnosis, a recent lab value, a documented failed trial of metformin. And North Carolina did both in sequence: obesity coverage was discontinued effective October 1, 2025, citing state funding shortfalls, and reinstated effective December 12, 2025 by the governor's directive. If you want one fact to carry away from this page, it is that last one. This is a benefit that can move twice in a quarter.
Several of these programs cover a GLP-1 and then rank them, so the molecule you get is the one the state prefers rather than the one you were prescribed. That matters because the two approved products are not substitutes on paper: the semaglutide label carries a cardiovascular indication[3] and the tirzepatide label carries a sleep apnea one[4], and a state document written about one of those uses does not reach the other. A transferred prescription for a non-preferred product is a denial waiting to happen rather than a refill.
What does Medicaid cover in your state?
Each state guide quotes what that state decided about paying for a GLP-1, from the state's own documents, with a link to the source. All 51 are below.
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Why this page is also a cash-price page
For most readers this is the page that explains why they are on a telehealth site at all. A program that excludes weight-loss agents has not made a clinical judgment about you; it has exercised a permission Congress wrote in 1990 and has never withdrawn. What follows from it is a cash purchase, and a cash purchase is a different set of questions: what the cash market charges, what a membership fee buys on top of the medication, and the calculator, which is where a headline price and a monthly cost stop being the same number.
- Check your own state's document rather than a summary of it, including ours. We date every fact and link the source; that is the point of the page.
- Check whether the restriction is an exclusion or a criteria set. An exclusion has no clinical route through it. A criteria set does, and it has paperwork attached.
- Check the effective date, not the publication date. Several of these documents carry a last-updated stamp that is not the date the rule starts.
- If the answer is no, price the cash route before you accept a program's first offer. How we verify prices explains what we count and what we refuse to count.
Questions people actually ask
Does Medicaid cover GLP-1 drugs for weight loss?
It depends entirely on the state. Federal law lists agents used for anorexia, weight loss or weight gain among the classes a program may exclude, so each state decides. Among the state programs we have documented, the answers range from a flat claim-level exclusion to coverage behind diabetes criteria.
Can I appeal a state Medicaid denial for a GLP-1?
That depends on which kind of no it is. Where the drug is excluded from the benefit outright, often implemented as a claim edit on the drug code, there is no clinical criteria to meet. Where the program requires prior authorization, there is a criteria set and a documented process.
Can a state change its mind?
Yes, and quickly. One program we documented discontinued obesity coverage effective October 1, 2025 citing state funding shortfalls, then reinstated it effective December 12, 2025 by the governor's directive, a week before the bulletin announcing it.
Why do the rules differ so much between states?
Because the federal statute grants permission rather than issuing a direction. It says these agents may be excluded or otherwise restricted. Everything after that is a budget decision, a drug utilization review board vote, or a formulary edit made state by state.
Sources
Primary sources and the claims they support.
- 1.42 U.S.C. 1396r-8 — Payment for covered outpatient drugs. Office of the Law Revision Counsel, United States Code, 2026. Source · Document dated September 2026Subsection (d)(2), the list of drugs or classes of drugs, or their medical uses, that may be excluded from coverage or otherwise restricted, carries as item (A) agents when used for anorexia, weight loss, or weight gain.
- 2.42 U.S.C. 1395w-102 — Prescription drug benefits. Office of the Law Revision Counsel, United States Code, 2026. Source · Document dated September 2026Subsection (e)(2)(A) excludes from the definition of a covered part D drug those drugs or classes of drugs, or their medical uses, that may be excluded or restricted under section 1396r-8(d)(2) as in effect on December 8, 2003, with named carve-outs for smoking cessation agents and certain barbiturates and benzodiazepines.
- 3.WEGOVY (semaglutide) injection and tablets — FDA prescribing information. DailyMed, National Library of Medicine, Structured Product Labeling, 2026. Source · Document dated June 2026The approved indications a state coverage document is deciding about: reduction of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; reduction and long-term maintenance of excess body weight in adults and in patients aged 12 and older with obesity, or adults with overweight plus a weight-related comorbid condition; and noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis, under accelerated approval.
- 4.ZEPBOUND (tirzepatide) injection — FDA prescribing information. DailyMed, National Library of Medicine, Structured Product Labeling, 2026. Source · Document dated August 2026The tirzepatide product's approved indications, which several state documents treat separately from the semaglutide ones: reduction and long-term maintenance of excess body weight, and treatment of moderate to severe obstructive sleep apnea in adults with obesity.
Key figures